Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.